Skip to content
Open access · CC-BY via OpenAlex

Revealing the role of metformin in gastric intestinal metaplasia treatment

Ruoyu Hu, Xia Xue, Xiangdong Sun, Yang Mi, Huijuan Wen, Huayuan Xi, Fuhao Li, Pengyuan Zheng, Simeng Liu

Frontiers in Pharmacology · 2024 · ▲ 9 citations

Abstract

Objective Gastric intestinal metaplasia (IM) is a precancerous stage associated with gastric cancer. Despite the observed beneficial effects of metformin on IM, its molecular mechanism remains not fully elucidated. This study aims to reveal the effects and potential mechanisms of metformin in treating IM based on both bioinformatics and in vivo investigations. Methods The seven public databases (GeneCards, DisGeNET, OMIM, SuperPred, Pharm Mapper, Swiss Target Prediction, TargetNet) were used in this work to identify targeted genes related to intestinal metaplasia (IM) and metformin. The shared targeted genes between metformin and IM were further analyzed by network pharmacology, while the interactions in-between were investigated by molecular docking. In parallel, the therapeutic effect of metformin was evaluated in IM mice model, while the core targets and pathways effected by metformin were verified in vivo. Results We screened out 1,751 IM-related genes and 318 metformin-targeted genes, 99 common genes identified in between were visualized by constructing the protein-protein interaction (PPI) network. The top ten core targeted genes were EGFR, MMP9, HIF1A, HSP90AA1, SIRT1, IL2, MAPK8, STAT1, PIK3CA, and ICAM1. The functional enrichment analysis confirmed that carcinogenesis and HIF-1 signaling pathways were primarily involved in the metformin treatment of IM. Based on molecular docking and dynamics, we found metformin affected the function of its targets by inhibiting receptor binding. Furthermore, metformin administration reduced the progression of IM lesions in Atp4a−/− mice model significantly. Notably, metformin enhanced the expression level of MUC5AC, while inhibited the expression level of CDX2. Our results also showed that metformin modulated the expression of core targets in vivo by reducing the activity of NF-κB and the PI3K/AKT/mTOR(definition)/HIF-1α signaling pathway. Conclusion This study confirms that metformin improves the efficacy of IM treatment by regulating a complex molecular network. Metformin plays a functional role in inhibiting inflammation/apoptosis-related pathways of further IM progression. Our work provides a molecular foundation for understanding metformin and other guanidine medicines in IM treatment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.3389/fphar.2024.1340309
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Hu, R., Xue, X., Sun, X., Mi, Y., Wen, H., Xi, H., Li, F., Zheng, P., &amp; Liu, S. (2024). Revealing the role of metformin in gastric intestinal metaplasia treatment. <em>Frontiers in Pharmacology</em>. https://doi.org/10.3389/fphar.2024.1340309
Vancouver
Hu R, Xue X, Sun X, Mi Y, Wen H, Xi H, et al. Revealing the role of metformin in gastric intestinal metaplasia treatment. Frontiers in Pharmacology. 2024. doi:10.3389/fphar.2024.1340309.
BibTeX
@article{ruoyu2024Reveal, title = {Revealing the role of metformin in gastric intestinal metaplasia treatment}, author = {Ruoyu Hu and Xia Xue and Xiangdong Sun and Yang Mi and Huijuan Wen and Huayuan Xi and Fuhao Li and Pengyuan Zheng and Simeng Liu}, journal = {Frontiers in Pharmacology}, year = {2024}, doi = {10.3389/fphar.2024.1340309}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings